Search Articles :
Re-size text: Decrease Text Size Increase Text Size

Oncologists at the Stephenson Cancer Center Present the Latest in Immunotherapy and Targeted Therapies at the American Society of Clinical Oncology Annual Meeting

Monday, June 15, 2015 - Campus News -

Oncologists from the Stephenson Cancer Center at the University of Oklahoma presented their latest research findings at the annual meeting of the American Society of Clinical Oncology, the premiere scientific meeting for clinical and translational oncology. 

The annual meeting brings together more than 30,000 oncology professionals from around the world. 

Faculty members from the Stephenson Cancer Center were authors on 21 different abstracts at this year's annual meeting, a record-breaking number for the Center. Abstract submissions are reviewed through a rigorous selection process, and only abstracts of superior quality are selected. 

"To have such a large presence at ASCO, the largest professional oncology meeting in the world, reflects the caliber of research that our faculty members are conducting each day," said Robert S. Mannel, MD, Stephenson Cancer Center director. "I am especially proud that Stephenson Cancer Center oncologists are making significant contributions to the emerging field of precision medicine on a national level.

"This year's meeting highlighted two major areas of cancer research: immunotherapy treatments and targeted therapies. While these therapeutic strategies have shown early success in melanoma and a few other cancers, research presented at the meeting showed promising results in a number of other tumor types, including non-small cell lung cancer and some head and neck cancers. 

Many of these advanced immunotherapy treatments and targeted therapies are currently offered through clinical trials at the Stephenson Cancer Center. The Oklahoma TSET Phase I Program, located at the center, provides access to new and promising targeted therapies in the early stages of development. 

Supplementary Information The nine Stephenson Cancer Center faculty and staff listed below were authors on 21 different abstracts accepted at the 2015 annual meeting of the American Society of Clinical Oncology: 
  • Kathleen Moore, MD (10) 
  • Robert Mannel, MD (4)
  • Shubham Pant, MD (4)
  • Joan Walker, MD (4)
  • Lisa Landrum, MD (1)
  • D. Scott McMeekin, MD (1)
  • Katherine Moxley, MD (1)
  • Michael Sughrue, MD (1)
  • Wade Williams, PhD (1) 
Some highlights from these abstracts include: 

Kathleen Moore, MD, MS, presented promising findings on a phase I, first-in-human trial (abstract #5518) for patients with epithelial ovarian cancer. The study combines an anticancer agent with an antibody that is specifically targeted to the proteins expressed by the cancer. When the drug is administered, it allows a toxic agent to be delivered directly to the cancer cells. The study shows potential even in heavily pre-treated patients. 

Shubham Pant, MD, presented encouraging results in a study (abstract #4065) for patients with metastatic gastric and esophageal cancers who often have limited options. The new treatment being studied combines chemotherapy and more targeted therapies to attack the cancer. Initial results show that this new treatment option can be used safely and effectively. 

For media inquires, please call Claire Turmelle at (405) 271-1333. 

Related Articles:

No Related Content Found



Related Materials